Follitropin alfa biosimilar - Fertility Biotech

Drug Profile

Follitropin alfa biosimilar - Fertility Biotech

Alternative Names: AFOLIA; Bemfola; Bemfola Pen; Follitropin alfa solution pre-filled pen; Follitropin alpha biosimilar - Fertility Biotech; Follitropin-alfa; r-hFSH biosimilar - Fertility Biotech; recombinant human follicle-stimulating hormone - Fertility Biotech

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator FINOX
  • Developer Fertility Biotech; FINOX
  • Class Follicle stimulating hormones; Infertility therapies; Peptide fragments; Pituitary gonadotropins; Recombinant proteins
  • Mechanism of Action Chorionic gonadotropin stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility; Male infertility

Most Recent Events

  • 30 Nov 2015 Launched for Male infertility in European Union (SC)
  • 30 Nov 2015 Registered for Male infertility in European Union (SC)
  • 30 Nov 2015 Preregistration for Female infertility in Australia (SC) before 30 November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top